<article article-type="correction"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2720223</article-id><article-id pub-id-type="pii">6605234</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6605234</article-id><article-categories><subj-group subj-group-type="heading"><subject>Corrigendum</subject></subj-group></article-categories><title-group><article-title>A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khan</surname><given-names>O A</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ranson</surname><given-names>M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Michael</surname><given-names>M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Olver</surname><given-names>I</given-names></name></contrib><contrib contrib-type="author"><name><surname>Levitt</surname><given-names>N C</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mortimer</surname><given-names>P</given-names></name></contrib><contrib contrib-type="author"><name><surname>Watson</surname><given-names>A J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Margison</surname><given-names>G P</given-names></name></contrib><contrib contrib-type="author"><name><surname>Midgley</surname><given-names>R</given-names></name></contrib><contrib contrib-type="author"><name><surname>Middleton</surname><given-names>M R</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>28</day><month>07</month><year>2009</year></pub-date><pub-date pub-type="ppub"><day>04</day><month>08</month><year>2009</year></pub-date><volume>101</volume><issue>3</issue><fpage>550</fpage><lpage>550</lpage><copyright-statement>Copyright 2009, Cancer Research UK</copyright-statement><copyright-year>2009</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions></article-meta></front><body><p><bold><offsets xml_i="2373" xml_f="2387" txt_i="7" txt_f="21">Correction to:</offsets></bold><offsets xml_i="2394" xml_f="2395" txt_i="21" txt_f="22"> </offsets><italic><offsets xml_i="2403" xml_f="2428" txt_i="22" txt_f="47">British Journal of Cancer</offsets></italic><offsets xml_i="2437" xml_f="2445" txt_i="47" txt_f="55"> (2008) </offsets><bold><offsets xml_i="2451" xml_f="2453" txt_i="55" txt_f="57">98</offsets></bold><offsets xml_i="2460" xml_f="2477" txt_i="57" txt_f="74">, 1614–1618; doi:</offsets><related-article related-article-type="corrected-article" id="N0x3a2cfa0N0x34e9a90" ext-link-type="doi" xlink:href="10.1038/sj.bjc.6604366"><offsets xml_i="2617" xml_f="2639" txt_i="74" txt_f="96">10.1038/sj.bjc.6604366</offsets></related-article></p><p><offsets xml_i="2664" xml_f="2744" txt_i="97" txt_f="177">In the original submission and subsequent publication of the above paper in the </offsets><italic><offsets xml_i="2752" xml_f="2777" txt_i="177" txt_f="202">British Journal of Cancer</offsets></italic><offsets xml_i="2786" xml_f="2921" txt_i="202" txt_f="337"> last year, the authors failed to acknowledge the support of the ‘NIHR Biomedical Research Centre, Oxford' in carrying out their study.</offsets></p><p><offsets xml_i="2928" xml_f="2990" txt_i="338" txt_f="400">They are now grateful for the chance to correct this omission.</offsets></p></body></article>